Aminomixpery Injection

Adult administration

Adults: The dosage should be adjusted according to the patient's amino acid, glucose, electrolyte, fluid requirements, and clinical state and nutritional status. In intravenous nutrition, alongside the general principles and recommendations regarding amino acid, glucose, and electrolyte administration and dosage, fluid supplementation guidelines should also be considered. To meet additional caloric needs, lipid emulsions should be adequately administered intravenously. Maximum daily dosage: 40 mL/kg/day (equivalent to 1.4 g of amino acids/kg/day and 2.5 g of glucose/kg/day). Duration of treatment: The period of intravenous administration varies based on the patient's condition and nutritional requirements. Additional intravenous administration of lipids, vitamins, and further electrolytes and trace elements should be considered according to the patient's clinical condition.

This medication must be used strictly according to the physician's instructions, and if any signs of anaphylaxis, such as fever, chills, rash, or difficulty breathing occur during use, administration should be immediately discontinued. When used in conjunction with intravenous calcium-containing preparations, precipitation may occur if mixed with ceftriaxone, and the same infusion device should not be used; if it is necessary to use the same infusion line, it should be thoroughly rinsed before and after administration. This medication should not be administered to certain patients, such as those with hypersensitivity to the components or congenital amino acid metabolism disorders, patients where the risk of fluid overload is contraindicated (e.g., with heart failure or pulmonary edema), those with severe liver or kidney dysfunction, patients with a history of myocardial infarction, and children under 2 years of age. Special precautions are required for patients with liver, kidney, heart diseases, diabetes, or electrolyte imbalances; regular monitoring and management of blood glucose, urea, ammonia, and electrolyte levels are necessary. This medication may cause injection site irritation, thrombophlebitis, allergic reactions, etc., so the injection site should be checked frequently, and any unusual symptoms should be addressed immediately. When starting treatment in patients with malnutrition, there is a risk of refeeding syndrome, and the infusion rate should be adjusted slowly with monitoring. During catheter insertion, strict aseptic procedures must be followed to reduce infection risk, and care must be taken not to exceed the recommended infusion rate. This medication contains glucose, potassium, and sodium, so care should be taken considering the component levels when administering it to patients with diabetes or impaired renal function. Safety has not been established for pregnant or nursing women, and it should only be administered when the therapeutic benefits outweigh the risks. Do not use if the packaging is damaged or if the contents are cloudy or contain particulates, and use mixed solutions immediately, discarding any remaining solution. Storage should be in a sealed container to avoid contact with air and kept at room temperature between 1 and 30 degrees Celsius. This storage method will maintain the medication’s effectiveness and prevent deterioration.

Serious side effects

Anaphylactic reactions (fever, chills, rash, breathing difficulties), pulmonary edema, shock, severe rash with high fever, increased serum osmolality, electrolyte disturbances, edema, liver dysfunction, kidney dysfunction, hyperaminoacidemia, hyperosmolality, acid-base imbalance

Mild side effects

Injection site irritation, thrombophlebitis, nausea, vomiting, tremors, sweating, increased body temperature, hyperglycemia, general adverse reactions of amino acid solutions

This medication should be stored in a sealed container to avoid contact with air and should ideally be kept at room temperature between 1 and 30 degrees Celsius. This storage method preserves the medication's efficacy and prevents degradation.

Appearance

This medication is a clear, colorless to pale yellow solution without any particulates, contained in a bag divided into two compartments.

Package unit

1000 mL/bag [x 1 (Component A: 500 mL, Component B: 500 mL)], 1000 mL/bag [x 6 (Component A: 500 mL, Component B: 500 mL)], 1500 mL/bag [x 1 (Component A: 750 mL, Component B: 750 mL)], 1500 mL/bag [x 4 (Component A: 750 mL, Component B: 750 mL)], 2000 mL/bag [x 1 (Component A: 1000 mL, Component B: 1000 mL)], 200